Laverman, PeterPeterLavermanJoosten, LiekeLiekeJoostenEek, AnnemarieAnnemarieEekRoosenburg, SusanSusanRoosenburgPeitl, Petra KolencPetra KolencPeitlMaina, TheodosiaTheodosiaMainaMäcke, HelmutHelmutMäckeAloj, LuigiLuigiAlojvon Guggenberg, ElisabethElisabethvon GuggenbergSosabowski, Jane KJane KSosabowskide Jong, MarionMarionde JongReubi-Kattenbusch, Jean-ClaudeJean-ClaudeReubi-KattenbuschOyen, Wim J GWim J GOyenBoerman, Otto COtto CBoerman2024-10-112024-10-112011https://boris-portal.unibe.ch/handle/20.500.12422/76183Cholecystokinin 2 (CCK-2) receptor overexpression has been demonstrated in various tumours such as medullary thyroid carcinomas and small-cell lung cancers. Due to this high expression, CCK-2 receptors might be suitable targets for radionuclide imaging and/or radionuclide therapy. Several CCK-2 receptor-binding radiopeptides have been developed and some have been tested in patients. Here we aimed to compare the in vivo tumour targeting properties of 12 (111)In-labelled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated gastrin/CCK2 receptor-binding peptides.en500 - Science::570 - Life sciences; biology600 - Technology::610 - Medicine & healtharticle10.48350/55612146173200029227270000210.1007/s00259-011-1806-0